vorinostat has been researched along with Cancer of the Thyroid in 12 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy." | 2.48 | Novel molecular targeted therapies for refractory thyroid cancer. ( Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES, 2012) |
| "In both, thyroid cancer is driven by overactivation of PI3K-AKT signaling." | 1.43 | SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model. ( Cheng, SY; Kim, DW; Willingham, MC; Zhao, L; Zhu, X, 2016) |
| "Seven thyroid cancer cell lines (SNU-790, BCPAP, KTC1, TPC1, TPC1-M, KTC2, and FRO) and four HIF1α inhibitors (echinomycin, LAQ824, temsirolimus, and vorinostat) were used in the present study." | 1.42 | Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer. ( Ahn, SH; Cha, W; Jeon, EH; Jeong, WJ; Kim, DW; Kim, SD, 2015) |
| " The objective of this study was to investigate the effects of 1,25(OH)(2)D(3) and the superagonistic analog CD578 in anaplastic thyroid cancer, alone or in combination with paclitaxel, a taxane, and suberoylanilide hydroxamic acid (SAHA), a potent histone deacetylase inhibitor with promising effects in undifferentiated thyroid cancer." | 1.37 | 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. ( Bouillon, R; Clinckspoor, I; Decallonne, B; Korch, C; Mathieu, C; Overbergh, L; Verlinden, L; Verstuyf, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, W | 1 |
| Kim, DW | 2 |
| Kim, SD | 1 |
| Jeon, EH | 1 |
| Jeong, WJ | 1 |
| Ahn, SH | 1 |
| Kim, SH | 1 |
| Kang, JG | 1 |
| Kim, CS | 1 |
| Ihm, SH | 1 |
| Choi, MG | 1 |
| Yoo, HJ | 1 |
| Lee, SJ | 1 |
| Zhu, X | 1 |
| Zhao, L | 1 |
| Willingham, MC | 1 |
| Cheng, SY | 1 |
| Ning, L | 1 |
| Jaskula-Sztul, R | 1 |
| Kunnimalaiyaan, M | 1 |
| Chen, H | 1 |
| Woyach, JA | 1 |
| Kloos, RT | 1 |
| Ringel, MD | 1 |
| Arbogast, D | 1 |
| Collamore, M | 1 |
| Zwiebel, JA | 1 |
| Grever, M | 1 |
| Villalona-Calero, M | 1 |
| Shah, MH | 1 |
| Borbone, E | 1 |
| Berlingieri, MT | 1 |
| De Bellis, F | 1 |
| Nebbioso, A | 1 |
| Chiappetta, G | 1 |
| Mai, A | 1 |
| Altucci, L | 1 |
| Fusco, A | 1 |
| Hou, P | 1 |
| Bojdani, E | 1 |
| Xing, M | 1 |
| Clinckspoor, I | 1 |
| Verlinden, L | 1 |
| Overbergh, L | 1 |
| Korch, C | 1 |
| Bouillon, R | 1 |
| Mathieu, C | 1 |
| Verstuyf, A | 1 |
| Decallonne, B | 1 |
| Perez, CA | 1 |
| Santos, ES | 1 |
| Arango, BA | 1 |
| Raez, LE | 1 |
| Cohen, EE | 1 |
| Dom, G | 1 |
| Galdo, VC | 1 |
| Tarabichi, M | 1 |
| Tomás, G | 1 |
| Hébrant, A | 1 |
| Andry, G | 1 |
| De Martelar, V | 1 |
| Libert, F | 1 |
| Leteurtre, E | 1 |
| Dumont, JE | 1 |
| Maenhaut, C | 1 |
| van Staveren, WC | 1 |
| Mitsiades, CS | 1 |
| Poulaki, V | 1 |
| McMullan, C | 1 |
| Negri, J | 1 |
| Fanourakis, G | 1 |
| Goudopoulou, A | 1 |
| Richon, VM | 1 |
| Marks, PA | 1 |
| Mitsiades, N | 1 |
| Luong, QT | 1 |
| O'Kelly, J | 1 |
| Braunstein, GD | 1 |
| Hershman, JM | 1 |
| Koeffler, HP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma[NCT00134043] | Phase 2 | 19 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR., or similar definition that is accurate and appropriate." (NCT00134043)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| PR (Partial Response) | CR (Complete Response) | Stable disease | |
| DTCs (Well-differentiated Thyroid Carcinomas) | 0 | 0 | 56 |
| MTC (Medullary Thyroid Cancer) | 0 | 0 | 0 |
1 review available for vorinostat and Cancer of the Thyroid
| Article | Year |
|---|---|
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; B | 2012 |
1 trial available for vorinostat and Cancer of the Thyroid
| Article | Year |
|---|---|
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Enzy | 2009 |
10 other studies available for vorinostat and Cancer of the Thyroid
| Article | Year |
|---|---|
Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer.
Topics: Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplast | 2015 |
The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Syner | 2016 |
SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
Topics: Adenocarcinoma, Follicular; Animals; Carcinogenesis; Disease Models, Animal; Hydroxamic Acids; Mice, | 2016 |
Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Carcinoma, Medu | 2008 |
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Carcinoma; Cell Line; Cell Line, Tumor; Cell Prol | 2010 |
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.
Topics: Cell Line, Tumor; Gene Expression Regulation; Humans; Hydroxamic Acids; Intracellular Signaling Pept | 2010 |
1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cell Cycle; Cell Line, Tumor; Cell Proli | 2011 |
5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma; Cell Differentiation; Cell Line, | 2013 |
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Death; Cinnamates; Down-Regulation; Gene Expressio | 2005 |
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Carboplatin; Carcinoma; Cell Cycle Pr | 2006 |